PMID- 24463293
OWN - NLM
STAT- MEDLINE
DCOM- 20141218
LR  - 20231110
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 15
IP  - 2
DP  - 2014 Jan 23
TI  - Use of genetically modified mesenchymal stem cells to treat neurodegenerative 
      diseases.
PG  - 1719-45
LID - 10.3390/ijms15021719 [doi]
AB  - The transplantation of mesenchymal stem cells (MSCs) for treating 
      neurodegenerative disorders has received growing attention recently because these 
      cells are readily available, easily expanded in culture, and when transplanted, 
      survive for relatively long periods of time. Given that such transplants have 
      been shown to be safe in a variety of applications, in addition to recent 
      findings that MSCs have useful immunomodulatory and chemotactic properties, the 
      use of these cells as vehicles for delivering or producing beneficial proteins 
      for therapeutic purposes has been the focus of several labs. In our lab, the use 
      of genetic modified MSCs to release neurotrophic factors for the treatment of 
      neurodegenerative diseases is of particular interest. Specifically, glial 
      cell-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and brain 
      derived neurotrophic factor (BDNF) have been recognized as therapeutic trophic 
      factors for Parkinson's, Alzheimer's and Huntington's diseases, respectively. The 
      aim of this literature review is to provide insights into: (1) the inherent 
      properties of MSCs as a platform for neurotrophic factor delivery; (2) the 
      molecular tools available for genetic manipulation of MSCs; (3) the rationale for 
      utilizing various neurotrophic factors for particular neurodegenerative diseases; 
      and (4) the clinical challenges of utilizing genetically modified MSCs.
FAU - Wyse, Robert D
AU  - Wyse RD
AD  - Field Neurosciences Institute Laboratory for Restorative Neurology, Brain 
      Research and Integrative Neuroscience Center, Program in Neuroscience, Central 
      Michigan University, Mount Pleasant, MI 48859, USA. wyse1r@cmich.edu.
FAU - Dunbar, Gary L
AU  - Dunbar GL
AD  - Field Neurosciences Institute Laboratory for Restorative Neurology, Brain 
      Research and Integrative Neuroscience Center, Program in Neuroscience, Central 
      Michigan University, Mount Pleasant, MI 48859, USA. dunba1g@cmich.edu.
FAU - Rossignol, Julien
AU  - Rossignol J
AD  - Field Neurosciences Institute Laboratory for Restorative Neurology, Brain 
      Research and Integrative Neuroscience Center, Program in Neuroscience, Central 
      Michigan University, Mount Pleasant, MI 48859, USA. rossi1j@cmich.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140123
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
SB  - IM
MH  - Animals
MH  - Cell- and Tissue-Based Therapy
MH  - Gene Transfer Techniques
MH  - *Genetic Therapy
MH  - Humans
MH  - *Mesenchymal Stem Cell Transplantation
MH  - Mesenchymal Stem Cells/*metabolism
MH  - Neurodegenerative Diseases/*genetics/*therapy
MH  - *Transduction, Genetic
PMC - PMC3958818
EDAT- 2014/01/28 06:00
MHDA- 2014/12/19 06:00
PMCR- 2014/02/01
CRDT- 2014/01/28 06:00
PHST- 2013/12/02 00:00 [received]
PHST- 2013/12/18 00:00 [revised]
PHST- 2014/01/14 00:00 [accepted]
PHST- 2014/01/28 06:00 [entrez]
PHST- 2014/01/28 06:00 [pubmed]
PHST- 2014/12/19 06:00 [medline]
PHST- 2014/02/01 00:00 [pmc-release]
AID - ijms15021719 [pii]
AID - ijms-15-01719 [pii]
AID - 10.3390/ijms15021719 [doi]
PST - epublish
SO  - Int J Mol Sci. 2014 Jan 23;15(2):1719-45. doi: 10.3390/ijms15021719.